EdMedRxP Clinical Knowledge. Precision Prescribing.

EdMedRxP

Clinical Knowledge. Precision Prescribing.

Latest Articles

Prescribed Into Deficiency: How Common Drug Regimens Silently Drain the Nutrients Your Patients Need Most
Prescribing Practice & Policy

Prescribed Into Deficiency: How Common Drug Regimens Silently Drain the Nutrients Your Patients Need Most

A growing body of evidence confirms that many of the most frequently prescribed drug classes systematically deplete essential vitamins, minerals, and enzymatic cofactors—generating a cascade of symptoms that too often leads to additional prescriptions rather than root-cause recognition. Understanding which medications carry the highest depletion burden, and how to audit a patient's regimen accordingly, is becoming a core competency for precision prescribers. This article provides a structured cl
Old Faithful: The Clinical Case for Choosing Established Medications Over Newer Alternatives
Prescribing Practice & Policy

Old Faithful: The Clinical Case for Choosing Established Medications Over Newer Alternatives

The relentless introduction of new pharmaceutical agents creates pressure on clinicians to prescribe the latest options, even when decades of evidence support older, less expensive alternatives. This article examines the structural forces—marketing, formulary design, and medicolegal anxiety—that distort prescribing decisions, and offers a defensible framework for selecting established agents when the clinical evidence genuinely favors them.
Clearing the Chart: The Clinical and Economic Imperative of Penicillin Allergy De-Labeling
Prescribing Practice & Policy

Clearing the Chart: The Clinical and Economic Imperative of Penicillin Allergy De-Labeling

An estimated 10% of US patients carry a penicillin allergy label in their medical record, yet the vast majority have never experienced a true IgE-mediated reaction. Systematic de-labeling protocols offer clinicians a structured pathway to restore access to first-line therapy, reduce antimicrobial resistance, and improve patient outcomes across care settings.
Labeled Into a Corner: How Narrow FDA Indications Leave Clinicians—and Patients—Without Options
Prescribing Practice & Policy

Labeled Into a Corner: How Narrow FDA Indications Leave Clinicians—and Patients—Without Options

FDA-approved indications represent a regulatory floor, not a clinical ceiling—yet the downstream consequences of narrow labeling routinely block patients from therapies that peer-reviewed evidence strongly supports. This article examines the regulatory, liability, and payer forces that sustain these barriers, and offers a structured framework for clinicians navigating prior authorization denials and building defensible off-label rationale.
Shorter, Smarter, Safer: Rethinking Antibiotic Duration in the Age of Resistance
Prescribing Practice & Policy

Shorter, Smarter, Safer: Rethinking Antibiotic Duration in the Age of Resistance

Decades of clinical habit have conditioned both prescribers and patients to equate longer antibiotic courses with greater therapeutic certainty—yet a growing body of evidence challenges this assumption directly. Duration-optimized antibiotic therapy is emerging as a cornerstone of responsible antimicrobial stewardship, offering comparable efficacy with measurable reductions in resistance emergence, adverse effects, and cost. This article provides clinicians with a practical, evidence-anchored fr
Treating More, Achieving Less: Recognizing and Reversing the Clinical Harm of Therapeutic Accumulation
Prescribing Practice & Policy

Treating More, Achieving Less: Recognizing and Reversing the Clinical Harm of Therapeutic Accumulation

In complex patients, the reflex to add a medication for every uncontrolled variable can quietly erode the very outcomes clinicians are working to improve. This article examines the mechanisms through which therapeutic accumulation undermines care and offers a structured framework for determining when a medication genuinely serves the patient—and when it does not.
The Silent Saboteur: Why Undiagnosed Sleep Apnea Is Quietly Undermining Your Patient's Medication Regimen
Prescribing Practice & Policy

The Silent Saboteur: Why Undiagnosed Sleep Apnea Is Quietly Undermining Your Patient's Medication Regimen

Obstructive sleep apnea remains one of the most underdiagnosed conditions in primary and specialty care, yet its physiological consequences extend far beyond nocturnal hypoxemia. For prescribers across cardiology, psychiatry, and endocrinology, untreated sleep-disordered breathing may be quietly invalidating medication trials, distorting therapeutic endpoints, and generating false clinical failures. Understanding the mechanistic links between sleep pathology and drug response is no longer option
Prescribing Practice & Policy

Prescribing Without a Roadmap: A Structured Approach to Off-Label Therapy in Rare Disease

When FDA-approved therapies do not exist or fall short for patients with rare diseases, off-label prescribing becomes a clinical and ethical necessity—but one fraught with liability exposure, coverage obstacles, and evidentiary uncertainty. This article provides US clinicians with a structured framework for making defensible off-label prescribing decisions grounded in published evidence, transparent communication, and sound clinical reasoning.
Clinical Pharmacology

Timing Is the Prescription: What Circadian Biology Means for Modern Drug Therapy

Emerging evidence in chronopharmacology reveals that when a drug is administered can be as consequential as how much is given. This article examines the physiological basis of circadian-dependent drug behavior and translates the science into actionable, evidence-informed timing strategies for US clinicians managing common chronic conditions.
Hiding in Plain Sight: The Supplement-Drug Interactions Clinicians Can No Longer Afford to Overlook
Prescribing Practice & Policy

Hiding in Plain Sight: The Supplement-Drug Interactions Clinicians Can No Longer Afford to Overlook

Millions of American patients take dietary supplements alongside prescription medications without disclosing this to their providers—creating a hidden layer of pharmacological complexity that can silently erode therapeutic outcomes. This article equips prescribers with a structured screening framework, illustrative case scenarios, and evidence-based guidance on which supplement-drug combinations demand immediate clinical intervention versus targeted patient counseling.
Clinical Pharmacology

Beyond the Standard Dose: Building an Individualized Dosing Strategy for the Modern Patient

Standard dosing recommendations, derived from population-level clinical trial data, frequently fail to account for the physiological heterogeneity of individual patients—leading to subtherapeutic outcomes or preventable toxicity. This article examines the clinical tools, pharmacokinetic principles, and practical implementation strategies that enable prescribers to move beyond uniform dosing toward approaches tailored to renal function, body composition, age, and disease state.
Clinical Pharmacology

Reading the Patient, Not Just the Genome: The Clinical Case for Phenotypic Metabolic Profiling in Drug Selection

Pharmacogenomic testing has captured significant clinical attention, but genotype alone offers an incomplete picture of how any individual patient will metabolize a given drug. This article makes the case for phenotypic metabolic profiling—a dynamic, integrative approach that incorporates organ function, age-related physiological changes, drug-drug interactions, and real-time clinical data to refine prescribing decisions. For clinicians navigating the complexity of modern therapeutics, phenotypi
Prescribing Practice & Policy

Prescribing for the Real World: How Clinicians Can Engineer Better Medication Adherence from the First Encounter

Medication non-adherence costs the US healthcare system an estimated $300 billion annually and contributes to nearly 125,000 preventable deaths each year—yet it remains underaddressed at the point of prescribing. This article examines the layered psychological, socioeconomic, and logistical forces driving non-adherence, and equips clinicians with evidence-based behavioral strategies to close the gap between what is prescribed and what is actually taken. Moving beyond patient blame, it reframes t
Prescribing Practice & Policy

The Art of Subtraction: A Structured Clinical Approach to Deprescribing in Complex Medication Regimens

As polypharmacy continues to rise among aging and medically complex US patients, deprescribing has emerged as a critical—and underutilized—clinical skill. This roadmap walks prescribers through evidence-based protocols for identifying inappropriate medications, managing discontinuation safely, and communicating treatment changes in ways that preserve patient trust and reduce medicolegal exposure.
Pharmacogenomics at the Crossroads: Closing the Gap Between Genetic Evidence and Everyday Prescribing
Clinical Pharmacology

Pharmacogenomics at the Crossroads: Closing the Gap Between Genetic Evidence and Everyday Prescribing

Pharmacogenomic testing offers clinicians an unprecedented window into individual drug metabolism, yet widespread adoption in routine practice remains elusive. This article examines the structural, financial, and educational barriers that prevent CYP450 and TPMT testing from becoming standard of care—and offers practical frameworks for integrating genetic data into clinical workflows today.
Clinical Pharmacology

When Medications Collide: A Clinician's Guide to Cytochrome P450 Interactions in High-Risk Polypharmacy Regimens

Cytochrome P450 enzyme interactions remain one of the most underrecognized drivers of adverse drug reactions in patients managing multiple medications. This resource equips prescribers with structured tools for identifying, assessing, and mitigating high-risk CYP450 interactions before patient harm occurs. From real-world clinical scenarios to evidence-based deprescribing frameworks, this guide bridges pharmacokinetic theory and frontline practice.
Prescribing Practice & Policy

GLP-1 Agonists in Uncharted Territory: What Prescribers Must Know About Expanded Indications, Coverage Gaps, and Ethical Practice in 2024

GLP-1 receptor agonists have moved far beyond their origins as glucose-lowering agents, generating intense clinical interest and patient demand across weight management, cardiovascular medicine, and emerging therapeutic areas. Yet the prescribing landscape in 2024 is defined as much by insurance inconsistencies and ethical complexity as it is by promising clinical evidence. This article provides healthcare providers with practical guidance on navigating FDA approvals, off-label prescribing oblig